Alpha 2.0
Login Register
» Authors » Achim Steup

Achim Steup

Explore the profile of Achim Steup including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 15
Citations 354
Followers 0
Related Specialties
Pharmacology
General Medicine
Neurology
Top 10 Co-Authors
Bernd Lange
Akiko Okamoto
Christine Rauschkolb
Brigitte Kuperwasser
Mila S Etropolski
Mila Etropolski
Thomas Haufel
Paul Abrams
Ilse Van Hove
Mathilde Kaper
Published In
Neurourol Urodyn
Curr Med Res Opin
Arch Environ Health
Adv Ther
Pain Pract
Affiliations
Soon will be listed here.
Recent Articles
1.
Safety and efficacy of an α -blocker plus mirabegron compared with an α -blocker plus antimuscarinic in men with lower urinary tract symptoms secondary to benign prostatic hyperplasia and overactive bladder: A systematic review and network...
Herschorn S, Tarcan T, Jiang Y, Chung E, Hadi F, Steup A, et al.
Neurourol Urodyn . 2024 Jan; 43(3):604-619. PMID: 38291827
Aim: Antimuscarinics and the β3-adrenoreceptor agonist, mirabegron, are commonly used for treating patients with overactive bladder (OAB) and α -adrenoreceptor antagonists (α -blockers) are the main pharmacological agents used for...
2.
Predicting Mirabegron Treatment Response in Patients with Overactive Bladder: A Post Hoc Analysis of Data from Clinical Trials
Matta R, Saskin R, Neu S, Locke J, Kowalczyk A, Steup A, et al.
Eur Urol Focus . 2023 Apr; 9(6):957-965. PMID: 37120417
Background: Many patients discontinue overactive bladder (OAB) treatment because of unmet treatment expectations and/or tolerability issues. Objective: To develop a model for predicting the individual treatment response to mirabegron using...
3.
Efficacy and safety of mirabegron in children and adolescents with neurogenic detrusor overactivity: An open-label, phase 3, dose-titration study
Baka-Ostrowska M, Bolong D, Persu C, Tondel C, Steup A, Lademacher C, et al.
Neurourol Urodyn . 2021 May; 40(6):1490-1499. PMID: 34058027
Aims: To evaluate the efficacy and safety of mirabegron in children and adolescents (aged 3 to <18 years) with neurogenic detrusor overactivity (NDO) using clean intermittent catheterization. Methods: In this...
4.
What are the additional signs and symptoms in patients with detrusor underactivity and coexisting detrusor overactivity?
Gammie A, Kaper M, Steup A, Yoshida S, Dorrepaal C, Kos T, et al.
Neurourol Urodyn . 2018 Apr; 37(7):2220-2225. PMID: 29635760
Aims: This study aimed to determine what difference the inclusion of patients with coexisting detrusor overactivity (DO) makes to the signs and symptoms of patients with detrusor underactivity (DU). Methods:...
5.
Signs and symptoms that distinguish detrusor underactivity from mixed detrusor underactivity and bladder outlet obstruction in male patients
Gammie A, Kaper M, Steup A, Yoshida S, Dorrepaal C, Kos T, et al.
Neurourol Urodyn . 2018 Jan; 37(4):1501-1505. PMID: 29356059
Aims: This study aimed to identify signs and symptoms which show differences between men with detrusor underactivity (DU) compared to those with both DU and bladder outlet obstruction (BOO). Methods:...
6.
Tapentadol prolonged-release for moderate-to-severe chronic osteoarthritis knee pain: a double-blind, randomized, placebo- and oxycodone controlled release-controlled study
Serrie A, Lange B, Steup A
Curr Med Res Opin . 2017 May; 33(8):1423-1432. PMID: 28537501
Objective: To assess efficacy and safety of tapentadol prolonged release (PR) for moderate-to-severe chronic osteoarthritis knee pain. Methods: Patients (n = 990) were randomized (1:1:1) to tapentadol PR, oxycodone controlled...
7.
Tapentadol prolonged release for managing moderate to severe, chronic malignant tumor-related pain
Kress H, Koch E, Kosturski H, Steup A, Karcher K, Lange B, et al.
Pain Physician . 2014 Jul; 17(4):329-43. PMID: 25054392
Background: Tapentadol prolonged release (PR) is effective and well tolerated for chronic osteoarthritis, low back, and diabetic peripheral neuropathic pain. Objectives: To evaluate the efficacy and tolerability of tapentadol PR...
8.
A pooled analysis of patient-specific factors and efficacy and tolerability of tapentadol extended release treatment for moderate to severe chronic pain
Etropolski M, Lange B, Goldberg J, Steup A, Rauschkolb C
J Opioid Manag . 2013 Dec; 9(5):343-56. PMID: 24353047
Objective: To evaluate via retrospective analysis the efficacy and tolerability of tapentadol extended release (ER; 100-250 mg bid) based on patient-specific factors, including baseline pain intensity, prior opioid experience, gender,...
9.
Long-term safety and tolerability of tapentadol extended release for the management of chronic low back pain or osteoarthritis pain
Wild J, Grond S, Kuperwasser B, Gilbert J, McCann B, Lange B, et al.
Pain Pract . 2010 Jul; 10(5):416-27. PMID: 20602712
Background: Tapentadol is a novel, centrally acting analgesic with 2 mechanisms of action: µ-opioid receptor agonism and norepinephrine reuptake inhibition. This randomized, open-label phase 3 study (ClinicalTrials.gov Identifier: NCT00361504) assessed...
10.
Efficacy and safety of Tapentadol extended release compared with oxycodone controlled release for the management of moderate to severe chronic pain related to osteoarthritis of the knee: a randomized, double-blind, placebo- and active-controlled...
Afilalo M, Etropolski M, Kuperwasser B, Kelly K, Okamoto A, Van Hove I, et al.
Clin Drug Investig . 2010 Jul; 30(8):489-505. PMID: 20586515
Background: Tapentadol is a novel, centrally acting analgesic with mu-opioid receptor agonist and norepinephrine reuptake inhibitor activity. Objective: to evaluate the efficacy and safety of Tapentadol extended release (ER) compared...